GoAI
Get started
bioAffinity Technologies, Inc. logo

bioAffinity Technologies, Inc.

BIAF

NASDAQHealthcareMedical - Diagnostics & Research

Open in GoAI

Regular session

$5.9745

−$0.0255 · -0.43%

Aug 24, 10:41 AM ET

BIAF company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Sell

Trim exposure — unfavorable risk-reward

Valuation

36

Expensive

Momentum

23

Weakening

Sentiment

56

Mixed

Risk resilience

34

High Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

As a biotechnology enterprise, bioAffinity Technologies, Inc. is dedicated to pioneering both non-invasive diagnostic solutions and precision therapeutics for cancer. Its portfolio features CyPath lung, a specialized diagnostic test designed for the early identification of lung cancer. Beyond diagnostics, the firm actively explores targeted therapies intended to combat cancer at a cellular level. This San Antonio, Texas-based company commenced operations in 2014.

Industry
Medical - Diagnostics & Research
Sector
Healthcare
Headquarters
US
CEO
Maria Zannes
Listed since
Sep 1, 2022
Employees
57

Market position

Day range

Current $5.9745

52-week range

Current $5.9745

Open
$6.02
Previous close
$6.00
Volume
100.47K
0.25× average
Average volume
399.51K
Average daily volume
Market cap
2.5M USD
Beta
-1.05
Market reference 1
50-day average
$10.2776
-41.87% below average
200-day average
$22.9185
-73.93% below average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
-3.26M USD
P/E (TTM)
-0.05×
P/B (TTM)
0.55×
P/S (TTM)
0.42×
EV / EBITDA
0.23×
Earnings yield
-734.15%
Free cash flow yield
-462.33%
Dividend yield
0.00%

Profitability & efficiency

Gross margin
-39.57%
Operating margin
-209.82%
Net margin
-257.33%
Return on equity
-204.87%
Return on assets
-136.03%
Return on invested capital
-125.29%

Financial health

Debt / equity
0.38×
Current ratio
2.6×
Altman Z-score
-13.6
Piotroski F-score
3 of 9

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends17076%-50868%-118813%-186757%Gross margin, FY2022: 90.28%Gross margin, FY2023: 31.26%Gross margin, FY2024: 36.09%Gross margin, FY2025: 23.21%Operating margin, FY2022: -83511.51%Operating margin, FY2023: -314.89%Operating margin, FY2024: -95.63%Operating margin, FY2025: -171.58%Net margin, FY2022: -169771.25%Net margin, FY2023: -313.47%Net margin, FY2024: -96.56%Net margin, FY2025: -241.96%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2022 90.28%. Gross margin FY2023 31.26%. Gross margin FY2024 36.09%. Gross margin FY2025 23.21%. Operating margin FY2022 -83511.51%. Operating margin FY2023 -314.89%. Operating margin FY2024 -95.63%. Operating margin FY2025 -171.58%. Net margin FY2022 -169771.25%. Net margin FY2023 -313.47%. Net margin FY2024 -96.56%. Net margin FY2025 -241.96%.

Income trends

Revenue

6.16M USD-34.18%

Operating income

−10.57M USD-18.09%

Net income

−14.91M USD-64.93%
Income trends across reported periods11.79M USD2.08M USD−7.63M USD−17.34M USDRevenue, FY2022: 4.8K USDRevenue, FY2023: 2.53M USDRevenue, FY2024: 9.36M USDRevenue, FY2025: 6.16M USDOperating income, FY2021: −2.21M USDOperating income, FY2022: −4.01M USDOperating income, FY2023: −7.97M USDOperating income, FY2024: −8.95M USDOperating income, FY2025: −10.57M USDNet income, FY2021: −6.33M USDNet income, FY2022: −8.15M USDNet income, FY2023: −7.94M USDNet income, FY2024: −9.04M USDNet income, FY2025: −14.91M USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2022 4.8K USD. Revenue FY2023 2.53M USD. Revenue FY2024 9.36M USD. Revenue FY2025 6.16M USD. Operating income FY2021 −2.21M USD. Operating income FY2022 −4.01M USD. Operating income FY2023 −7.97M USD. Operating income FY2024 −8.95M USD. Operating income FY2025 −10.57M USD. Net income FY2021 −6.33M USD. Net income FY2022 −8.15M USD. Net income FY2023 −7.94M USD. Net income FY2024 −9.04M USD. Net income FY2025 −14.91M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue6.16M USD9.36M USD2.53M USD4.8K USD—
Cost of goods sold4.73M USD5.98M USD1.74M USD467 USD4.82K USD
Gross profit1.43M USD3.38M USD791.62K USD4.34K USD−4.82K USD
Research and development2.09M USD1.78M USD1.73M USD1.52M USD1.14M USD
Selling, general, and administrative9.91M USD9.94M USD6.79M USD2.48M USD1.07M USD
Operating expenses12M USD12.33M USD8.77M USD4.02M USD2.2M USD
Interest income23.39K USD17.61K USD122.13K USD46.71K USD424 USD
Interest expense44.37K USD92.48K USD37.13K USD2.53M USD1M USD
Depreciation and amortization504.84K USD605.64K USD249.59K USD10.18K USD4.82K USD
Operating income−10.57M USD−8.95M USD−7.97M USD−4.01M USD−2.21M USD
Net income−14.91M USD−9.04M USD−7.94M USD−8.15M USD−6.33M USD

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
55%
6 beats, 4 misses, 1 met estimate
Average EPS surprise
+27.01%
11 comparable reports
Latest EPS result
-0.64
Estimate -31.5 · Beat by 97.97%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates-0.54-11.69-22.83-33.97Q1 '25MissQ2 '25MetQ3 '25MissQ4 '25MissQ1 '26BeatQ2 '26BeatQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Mar 31, 2025: actual -6.31, estimate -4.2, surprise -50.24%, Miss. Q2 2025, reported May 15, 2025: actual -4.8, estimate -4.8, surprise 0.00%, Met estimate. Q3 2025, reported Aug 14, 2025: actual -5.1, estimate -3, surprise -70.00%, Miss. Q4 2025, reported Nov 14, 2025: actual -4.74, estimate -2.7, surprise -75.56%, Miss. Q1 2026, reported Mar 13, 2026: actual -1.11, estimate -2.7, surprise +58.89%, Beat. Q2 2026, reported May 8, 2026: actual -0.81, estimate -2.4, surprise +66.25%, Beat. Q3 2026, reported Aug 7, 2026: actual -0.64, estimate -31.5, surprise +97.97%, Beat. Q4 2026, reported Nov 18, 2026: actual —, estimate -2.1, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates2.51M2.07M1.62M1.17MQ1 '25MissQ2 '25MissQ3 '25MissQ4 '25BeatQ1 '26BeatQ2 '26MissQ3 '26MissQ4 '26Estimate
Q1 2025, reported Mar 31, 2025: actual 2.2M USD, estimate 2.42M USD, surprise -8.93%, Miss. Q2 2025, reported May 15, 2025: actual 1.85M USD, estimate 2.11M USD, surprise -12.11%, Miss. Q3 2025, reported Aug 14, 2025: actual 1.27M USD, estimate 1.51M USD, surprise -15.70%, Miss. Q4 2025, reported Nov 14, 2025: actual 1.45M USD, estimate 1.41M USD, surprise +2.49%, Beat. Q1 2026, reported Mar 13, 2026: actual 1.59M USD, estimate 1.55M USD, surprise +2.51%, Beat. Q2 2026, reported May 8, 2026: actual 1.35M USD, estimate 1.48M USD, surprise -8.87%, Miss. Q3 2026, reported Aug 7, 2026: actual 1.51M USD, estimate 1.7M USD, surprise -11.19%, Miss. Q4 2026, reported Nov 18, 2026: actual —, estimate 1.91M USD, surprise —, Comparison unavailable.

BIAF news

businesswire.com

bioAffinity Technologies Announces 1-for-15 Reverse Stock Split Effective at the Open of Trading on August 24, 2026

SAN ANTONIO--(BUSINESS WIRE)---- $BIAF #BIAF--bioAffinity Technologies will effect a 1-for-15 reverse split of its common stock at the opening of trading on Nasdaq on August 24, 2026.

Read source
businesswire.com

bioAffinity Technologies and AvMEDICAL Announce Nationwide Federal Healthcare Distribution Agreement for CyPath® Lung

SAN ANTONIO--(BUSINESS WIRE)---- $BIAF #AvMEDICAL--bioAffinity Technologies enters distribution agreement with AvMEDICAL to expand CyPath Lung sales reach and access to government healthcare systems.

Read source
prnewswire.com

WallachBeth Capital Announces Closing of bioAffinity Technologies $4M Private Placement Offering Priced At-the-Market Under Nasdaq Rules

JERSEY CITY, N.J., Aug. 14, 2026 /PRNewswire/ -- WallachBeth Capital LLC, a leading provider of capital markets and institutional execution services, announced that bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a…

Read source
businesswire.com

bioAffinity Technologies Announces Closing of $4M Private Placement Offering Priced At-the-Market Under Nasdaq Rules

SAN ANTONIO--(BUSINESS WIRE)---- $BIAF #BIAF--bioAffinity Technologies announces closing of $4M private placement offering.

Read source
prnewswire.com

WallachBeth Capital Announces bioAffinity Technologies Pricing of $4M Private Placement Offering Priced At-the-Market Under Nasdaq Rules

JERSEY CITY, N.J., , Aug. 13, 2026 /PRNewswire/ -- WallachBeth Capital LLC, a leading provider of capital markets and institutional execution services, announced that bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW),…

Read source
businesswire.com

bioAffinity Technologies Announces Pricing of $4M Private Placement Offering Priced At-the-Market Under Nasdaq Rules

SAN ANTONIO--(BUSINESS WIRE)---- $BIAF #BIAF--bioAffinity Technologies announces pricing of $4M private placement offering.

Read source

BIAF peers

Amgen Inc. logo

AMGN

Amgen Inc.

$440.72

+0.32%

Gilead Sciences, Inc. logo

GILD

Gilead Sciences, Inc.

$145.71

-0.28%

Vertex Pharmaceuticals Incorporated logo

VRTX

Vertex Pharmaceuticals Incorporated

$547.55

-0.09%

Intuitive Surgical, Inc. logo

ISRG

Intuitive Surgical, Inc.

$379.11

+0.08%

Sanofi logo

SNY

Sanofi

$45.6206

-0.50%

Regeneron Pharmaceuticals, Inc. logo

REGN

Regeneron Pharmaceuticals, Inc.

$825.22

-1.06%

ETFs holding BIAF

Funds reporting this stock among their holdings, ordered by reported position size.

Vanguard Extended Market ETF logoVanguard Extended Market ETFVXF
Market value
34.85K
Weight
0.00%
AUM
93.7B USD
Expense ratio
0.05%
Price / 1D
$244.04-0.61%

Continue in GoAI

Research BIAF

research.disclaimer